{"id":"NCT01421498","sponsor":"Shire","briefTitle":"Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","officialTitle":"A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-29","primaryCompletion":"2012-04-28","completion":"2012-04-28","firstPosted":"2011-08-22","resultsPosted":"2017-02-24","lastUpdate":"2021-06-11"},"enrollment":588,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca","Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"Lifitegrast","otherNames":["SAR 1118"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"5.0% Lifitegrast","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.","primaryOutcome":{"measure":"Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84","timeFrame":"Baseline (Day 0) to Day 84","effectByArm":[{"arm":"Lifitegrast 5.0%","deltaMin":-0.07,"sd":0.868},{"arm":"Placebo","deltaMin":0.17,"sd":0.819}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["24289915"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":293},"commonTop":["Instillation site irritation","Instillation site pain","Instillation site reaction","Dysgeusia","Visual acuity reduced"]}}